Second, could novel CAR constructs that integrate CD2 costimulatory domains while knocking out CD58 and/or CD54 surface molecules perform the dual functions of evading immune rejection and killing tumor cells that lack CD58 expression? This evidence concerns the gene CD2 and neoplasm.